Drug Profile
GeniusVac Mel4
Alternative Names: GeniusVacMel4; PDC*melLatest Information Update: 14 Jul 2023
Price :
$50
*
At a glance
- Originator PDC*line Pharma
- Developer PDC*line Pharma; University Hospital Grenoble
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Malignant melanoma
Most Recent Events
- 13 Jul 2023 Phase I development is ongoing for Malignant melanoma (Late-stage disease, Second-line therapy or greater) in France (PDC line Pharma pipeline, July 2023)
- 28 Mar 2021 No recent reports of development identified for phase-I development in Malignant-melanoma(Late-stage disease, Second-line therapy or greater) in France (SC, Injection)
- 01 Apr 2020 Pharmacodynamics and adverse event data from a phase I trial in Malignant melanoma released by PDC*line Pharma